Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Karina Kostbade"'
Autor:
Johanna Falkenhorst, Susanne Grunewald, Dawid Krzeciesa, Thomas Herold, Julia Ketzer, Miriam Christoff, Rainer Hamacher, Karina Kostbade, Jürgen Treckmann, Johannes Köster, Farhad Farzaliyev, Benjamin Samulon Fletcher, Nils Dieckmann, Moritz Kaths, Thomas Mühlenberg, Hans-Ulrich Schildhaus, Sebastian Bauer
Publikováno v:
Cancers, Vol 14, Iss 22, p 5496 (2022)
Circulating tumor DNA (ctDNA) from circulating free DNA (cfDNA) in GIST is of interest for the detection of heterogeneous resistance mutations and treatment monitoring. However, methodologies for use in a local setting are not standardized and are er
Externí odkaz:
https://doaj.org/article/11129c94a7be428c88418510ed3fe682
Autor:
Julius Roehrle, Stefan Kasper, Jürgen-Walter Treckmann, Peter Markus, Brigitte Schumacher, David Albers, Johanna Wendling, Saskia Ting, Bastian Mende, Marlene Maßmann, Maximilian Markus, Isabel Virchow, Vivian Rosery, Katharina Laue, Gregor Zaun, Karina Kostbade, Michael Pogorzelski, Timm M. Reissig, Sven-Thorsten Liffers, Kurt Schmid, Hans-Ulrich Schildhaus, Martin Schuler, Jens T. Siveke, Marcel Wiesweg
Publikováno v:
Oncology Research and Treatment. 46:140-150
Introduction: Systemic therapy is firmly established in patients with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). Clinical efficacy is still modest and options are limited. Combination therapy protocols such as FOLFIRINOX and gemc
Autor:
Rainer Hamacher, Jens T. Siveke, Ken Herrmann, Sebastian Bauer, Christoph Rischpler, Marit Ahrens, Martin Schuler, Ilektra A. Mavroeidi, Karina Kostbade, Lale Umutlu, Katharina Lueckerath, Maria Lippert, Manuel Weber, Justin Ferdinandus, Pedro Fragoso Costa, Lukas Kessler, Kim M. Pabst, Wolfgang P. Fendler
Supplementary Table from Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02a4ae5bf79f30815a2441bc9c85cca1
https://doi.org/10.1158/1078-0432.22486812
https://doi.org/10.1158/1078-0432.22486812
Autor:
Rainer Hamacher, Jens T. Siveke, Ken Herrmann, Sebastian Bauer, Christoph Rischpler, Marit Ahrens, Martin Schuler, Ilektra A. Mavroeidi, Karina Kostbade, Lale Umutlu, Katharina Lueckerath, Maria Lippert, Manuel Weber, Justin Ferdinandus, Pedro Fragoso Costa, Lukas Kessler, Kim M. Pabst, Wolfgang P. Fendler
Supplementary Figure from Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85ffec11431e82783ff6583a7dd7bb4f
https://doi.org/10.1158/1078-0432.22486815
https://doi.org/10.1158/1078-0432.22486815
Autor:
Rainer Hamacher, Jens T. Siveke, Ken Herrmann, Sebastian Bauer, Christoph Rischpler, Marit Ahrens, Martin Schuler, Ilektra A. Mavroeidi, Karina Kostbade, Lale Umutlu, Katharina Lueckerath, Maria Lippert, Manuel Weber, Justin Ferdinandus, Pedro Fragoso Costa, Lukas Kessler, Kim M. Pabst, Wolfgang P. Fendler
Purpose:We report efficacy and safety of 90Y-labeled FAPI-46 (90Y-FAPI-46-RLT) in patients with advanced sarcoma, pancreatic cancer, and other cancer entities.Experimental Design:Up to four cycles of radioligand therapy (RLT) were offered to patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ebc0da28647d60bdccf720680939ddc
https://doi.org/10.1158/1078-0432.c.6532392.v1
https://doi.org/10.1158/1078-0432.c.6532392.v1
Autor:
Wolfgang P. Fendler, Kim M. Pabst, Lukas Kessler, Pedro Fragoso Costa, Justin Ferdinandus, Manuel Weber, Maria Lippert, Katharina Lueckerath, Lale Umutlu, Karina Kostbade, Ilektra A. Mavroeidi, Martin Schuler, Marit Ahrens, Christoph Rischpler, Sebastian Bauer, Ken Herrmann, Jens T. Siveke, Rainer Hamacher
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(19)
Purpose: We report efficacy and safety of 90Y-labeled FAPI-46 (90Y-FAPI-46-RLT) in patients with advanced sarcoma, pancreatic cancer, and other cancer entities. Experimental Design: Up to four cycles of radioligand therapy (RLT) were offered to patie
Autor:
Justin, Ferdinandus, Pedro Fragoso, Costa, Lukas, Kessler, Manuel, Weber, Nader, Hirmas, Karina, Kostbade, Sebastian, Bauer, Martin, Schuler, Marit, Ahrens, Hans-Ulrich, Schildhaus, Christoph, Rischpler, Hong, Grafe, Jens T, Siveke, Ken, Herrmann, Wolfgang P, Fendler, Rainer, Hamacher
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 63(5)
Fibroblast activation protein (FAP) is overexpressed in several solid tumors and therefore represents an attractive target for radiotheranostic applications. Recent investigations demonstrated rapid and high uptake of small-molecule inhibitors of FAP
Autor:
Isabel Virchow, Karl Worm, Tanja Trarbach, Winfried Berger, Saskia Ting, Brigitte Schumacher, Tilman Steinmetz, Thomas Höhler, Johannes Meiler, Martin Schuler, Peter Reimer, Gabriele Linden, Stefan Kasper, Thomas Herold, Marcel Wiesweg, Kurt Werner Schmid, Peter Markus, Heike Knipp, Alexander Dechêne, Karina Kostbade, Andreas Paul, Henning Reis
Background The multicenter, single-arm, phase II study CEBIFOX evaluated the efficacy of a biweekly cetuximab administration in combination with FOLFOX6 as first-line therapy in KRAS (exon 2) wild-type (wt) metastatic colorectal cancer (mCRC). Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5696b5ebc448e4c4fa8e944cdfb072ca
https://www.ncbi.nlm.nih.gov/pubmed/32737003
https://www.ncbi.nlm.nih.gov/pubmed/32737003
Autor:
Henning Reis, Stefan Kasper, Martin Schuler, Brigitte Schumacher, Alexander Dechêne, Karl Worm, Gregor Zaun, Kurt Werner Schmid, Andreas Paul, Thomas Herold, Moritz Goetz, Nathalie Wolf, Tobias Köster, Peter Markus, Marcel Wiesweg, Karina Kostbade, Martin Metzenmacher, Isabel Virchow
Publikováno v:
Clinical Colorectal Cancer. 17:e331-e352
Deregulation of signal transduction pathways plays a critical role in oncogenesis of colorectal cancer (CRC) and directly affects sensitivity to targeted therapies. Against this background we developed a comprehensive biomarker profiling program incl
Autor:
Saskia Ting, Marcel Wiesweg, Henning Reis, Stefan Kasper, Daniel C. Christoph, Stefan Welter, Martin Schuler, Thomas Herold, U. Huber, Karl Worm, K.W. Schmid, Dirk Theegarten, Wilfried Eberhardt, Kaid Darwiche, Georgios Stamatis, R Karpf-Wissel, Karina Kostbade
Publikováno v:
Lung Cancer. 88:34-41
Objectives Pulmonary adenocarcinomas (ADC) can be sub-grouped based on dominant oncogenic drivers. EGFR mutations define an entity of metastatic ADC with favorable prognosis and high susceptibility to EGFR tyrosine kinase inhibition. In contrast, the